Table 1. Clinical features, evolution and biological characteristics of the ten CLL patients studied.

Samples	Follow-up (months)	Rai/Binet at diagnosis	Rai/Binet current stage	Cytogenetic alterations	Lymphocytes (µl)	CD19/CD5 (%)	ZAP-70	CD38 (%)	Rearrangement	IGHV homology	β2 microglobulin	LDH
CLL1	102	A/0	A/I	Trisomy 12	85,000	92	POSITIVE	12.5	IGVH1-2	100	1.4	417
CLL2	12	A/0	A/0 progressive	Rearrangement IgH	180,000	90	POSITIVE	14.4	IGHV3-11	99.6	12.5*	403
CLL3	108	A/I	A/I	del13q	55,000	80	NEGATIVE	3.9	IGHV1-2	94.3	1.4	325
CLL4	134	A/0	A/I	del13q	40,000	90	NEGATIVE	0.2	IGHV2-5	96.4	1.6	315
CLL5	1.5	B/II	B/II progressive	del17p13, c-myc amplification	170,000	94	POSITIVE	15.4	IGHV2-70	99.5	5.1	1044
CLL6	9	B/II	B/II	del13q	17,400	80	POSITIVE	0	IGHV3-21	98.6	1.7	523
CLL7	16	B/II	B/II progressive	Trisomy 12	53,000	93	POSITIVE	13	IGHV1-69	99.2	1.8	491
CLL8	34	A/0	A/0	del13q, del11q	10,300	62	NEGATIVE	5.4	DH	ND	2.1	321
CLL9	108	A/0	C/III progressive	del13q	171,000	96	NEGATIVE	0.1	IGHV3-21	92.8	2.2	572
CLL10	60	A/I	A/I	del13q	22,000	82	NEGATIVE	4.5	IGHV1-69	100	1.4	423

Summary of the prognosis factors considered in the clinic and genetic lesions that the ten patients harbor. ND = not done, del = deletion.